# Full-Life Technologies

Source: https://onco.cc/companies/full-life-technologies/  
OnCo record `full-life-technologies` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Full-Life Technologies makes medicines that carry a strongly radioactive particle, actinium-225, onto cancer cells so the radiation acts at short range. Its lead medicine is being tested in advanced prostate cancer and a second in lung and other solid tumours.

## Summary

Full-Life Technologies Limited describes itself as a privately held, fully integrated, clinical-stage actinium-based radiopharmaceutical company with operations in Belgium, Germany and China; its website description gives Shanghai as headquarters, and the trial sponsor is its UK subsidiary, Full-Life Technologies UK Limited. It attaches radionuclides to peptides, small molecules and single-domain antibodies. [225Ac]Ac-FL-020, a PSMA-targeted alpha radioconjugate, is in a global phase 1 trial in metastatic castration-resistant prostate cancer (NCT06492122), using an indium-111 labelled version for dosimetry; the company reported preliminary safety and PSA decline data at ESMO in October 2026. [225Ac]Ac-FL-261 targets c-MET and received US FDA IND clearance and Australian clearance in September 2026 for a phase 1/2 trial (NCT07873450) in c-MET overexpressing solid tumours, with an initial focus on non-squamous non-small cell lung cancer. A third, NTSR1-targeted small-molecule radioconjugate is in phase 1 under a collaboration with a partner, and earlier programmes target NPY1R and B7-H3. In August 2026 it completed construction of an actinium-225 manufacturing and radiolabelling facility in Gembloux, Belgium. Its first registered cancer trial, NCT06492122, was posted on ClinicalTrials.gov in July 2024.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- HQ: Shanghai
- Type: radiopharma
- Website: https://www.full-life.com/

## Notes

- Founding year not stated on the pages read on 29 October 2026; the milestones page did not render.
- Headquarters is taken from the site's own description ('headquartered in Shanghai, China with operations in Europe'); the overview page lists operations in Belgium, Germany and China, and recent releases are datelined London.
- No financing round is recorded because no company release with an amount was read.
- The ESMO 2026 FL-020 data were announced as encouraging; the numbers were not read.

## Sources

- Official website: https://www.full-life.com/
- About Full-Life: https://www.full-life.com/about-us
- Pipeline: https://www.full-life.com/radio/pipeline
- Press releases: https://www.full-life.com/media/press-releases
- ClinicalTrials.gov: phase 1 trial of [225Ac]Ac-FL-020 (NCT06492122): https://clinicaltrials.gov/study/NCT06492122
- ClinicalTrials.gov: SumMET phase 1/2 trial of [225Ac]Ac-FL-261 (NCT07873450): https://clinicaltrials.gov/study/NCT07873450

## Connected records

- cancers: [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- fronts: [Radiopharmaceuticals & Theranostics](https://onco.cc/fronts/radiopharma/)
- technologies: [Actinium-225 supply: thorium stocks, accelerators and radium targets](https://onco.cc/technologies/actinium-225-supply/), [Radioligand therapy (beta emitters)](https://onco.cc/technologies/radioligand-therapy/), [Targeted alpha therapy](https://onco.cc/technologies/targeted-alpha-therapy/)
- targets: [MET](https://onco.cc/targets/met/), [PSMA](https://onco.cc/targets/psma/)

---
JSON: https://onco.cc/api/v1/entities/full-life-technologies.json